Pharmacokinetic analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) time-course data allows estimation of quantitative parameters such as K trans (rate constant for plasma/interstitium contrast agent transfer), v e (extravascular extracellular volume fraction), and v p (plasma volume fraction). A plethora of factors in DCE-MRI data acquisition and analysis can affect accuracy and precision of these parameters and, consequently, the utility of quantitative DCE-MRI for assessing therapy response. In this multicenter data analysis challenge, DCE-MRI data acquired at one center from 10 patients with breast cancer before and after the first cycle of neoadjuvant chemotherapy were shared and processed with 12 software tools based on the Tofts model (TM), extended TM, and Shutter-Speed model. Inputs of tumor region of interest definition, pre-contrast T 1 , and arterial input function were controlled to focus on the variations in parameter value and response prediction capability caused by differences in models and associated algorithms. Considerable parameter variations were observed with the within-subject coefficient of variation (wCV) Tr a n s l a t i o n a l O n c o l o g y . The quantitative approach for DCE-MRI data analysis using pharmacokinetic models allows extraction and mapping of quantitative parameters of tumor biology in vivo. These parameters are usually variants of K trans , a rate constant for contrast agent (CA) molecule plasma/interstitium transfer, v e , the volume fraction of interstitial space (extracellular and extravascular, the putative CA distribution volume), and v p , the plasma volume fraction. The CA intravasation rate constant, k ep , can be calculated as K trans /v e . Recent workshops on both sides of the Atlantic have generated guidelines and recommendations on acquisition and analysis of DCE-MRI data for the purpose of assessing tumor therapy response [9] [10] [11] .
Introduction
With advances in targeted molecular therapy for cancer treatment, change in tumor size in response to therapy, which is routinely used in standard care for therapeutic monitoring, is often found to manifest later than changes in underlying tumor characteristics [1] [2] [3] [4] [5] [6] [7] [8] , such as vascularization and vascular permeability, cellularity, metabolism, and biochemistry. Thus, imaging modalities that can quantify tumor functions are becoming increasingly important for evaluation and prediction of therapy response. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a minimally invasive imaging method that measures changes in tissue microvascular properties and has been widely used in research or early phase clinical trial settings to provide assessment of tumor therapeutic response [1] [2] [3] [4] [5] [6] [7] [8] , as many cancer drugs affect tumor vasculature directly or indirectly [9] . The quantitative approach for DCE-MRI data analysis using pharmacokinetic models allows extraction and mapping of quantitative parameters of tumor biology in vivo. These parameters are usually variants of K trans , a rate constant for contrast agent (CA) molecule plasma/interstitium transfer, v e , the volume fraction of interstitial space (extracellular and extravascular, the putative CA distribution volume), and v p , the plasma volume fraction. The CA intravasation rate constant, k ep , can be calculated as K trans /v e . Recent workshops on both sides of the Atlantic have generated guidelines and recommendations on acquisition and analysis of DCE-MRI data for the purpose of assessing tumor therapy response [9] [10] [11] .
Unlike qualitative (such as description of curve shape) or semiquantitative (such as calculation of maximum signal change) analysis, the parameters derived from pharmacokinetic modeling of DCE-MRI time-course data should, in principle, be independent of MRI scanner platform (vendor and field strength), data acquisition details (pulse sequence and parameters), CA dose and/or injection rate, personnel skills, and so on, which makes them desirable imaging end points in multicenter clinical trial studies. However, the accuracy and precision of these parameters can be affected by a plethora of factors, including errors in quantification of pre-contrast T 1 [12] [13] [14] [15] and determination of arterial input function (AIF) [4, 9, 16, 17] , inadequate temporal resolution [9, 18, 19] or signal-to-noise ratio [15] , as well as selection of models to fit the data [9, 20, 21] . A recent study [22] comparing four commercial software packages for quantitative DCE-MRI data analysis has revealed considerable variability in pharmacokinetic parameter quantification from data sets of 15 subjects, with up to 74% within-subject coefficient of variation (wCV) among the tools, even though all four software packages were presumably based on the same Tofts model (TM) [23] . Commercialization of software tools for kinetic modeling of DCE-MRI data represents a necessary step for wide dissemination of DCE-MRI as a quantitative imaging biomarker in clinical trials and general practice. However, the poor reproducibility shown by this study among the available commercial solutions is one of the major obstacles in integration of quantitative DCE-MRI into standard care. Thorough comparison and validation of algorithms/ software tools for DCE-MRI data analysis are necessary within the context of monitoring tumor response to therapy.
Recognizing the importance of quantitative imaging for assessment of cancer response to therapy and rapid evaluation of the efficacy of new anticancer drugs, the National Cancer Institute has recently established the Quantitative Imaging Network (QIN) to provide resources for developing and validating quantitative imaging tools. The main mission of the QIN Image Analysis and Performance Metrics Working Group is to provide guidance and reach consensus on quantitative image analysis methods through comparison and validation of analysis algorithms. The available QIN infrastructure facilitates collaborative challenge projects involving multiple QIN centers. Here, we report the results from a DCE-MRI data analysis challenge project, in which several QIN centers performed analyses of DCE-MRI data from a digital reference object (DRO) [24] and human breast tumors using site-specific employment of algorithms/ software tools. The overall goal of the project was to compare and validate DCE-MRI data analysis tools available within the QIN. Because ultimately the utility of a quantitative imaging method for assessing cancer therapy response is judged by its robustness in evaluation/prediction of clinical and/or pathologic end points of response, the DCE-MRI pharmacokinetic parameters and their changes following therapy were correlated with pathologic response status of the patients with breast cancer to compare the capabilities of the algorithms/tools in predicting complete response versus noncomplete response.
Materials and Methods

DCE-MRI Challenge Participating QIN Centers
The QIN centers that participated in this DCE-MRI data analysis challenge project are Oregon Health and Science University (OHSU), Vanderbilt University (VU), University of Pittsburgh (UP), Brigham and Women's Hospital (BWH) and in collaboration with General Electric Research and Development (BWH-GE), University of Michigan (UM), University of Washington (UW), and Icahn School of Medicine at Mount Sinai (ISM). [23] and consisted of a single image slice of simulated DCE-MRI signal intensity time-course data (with 0.5-second temporal resolution) without noise in DICOM format with headers for both Siemens and GE scanner platforms. Each K trans and v e combination occupied a 10 × 10 pixel square area of the slice, allowing evaluation of reproducibility in fitting pixel data with the same K trans and v e combination. Details of simulated data acquisition parameters and fixed parameters used for the TM can be found in references [24] and [25] .
Simulated DRO DCE-MRI Data Sharing and Analysis
The DRO data were downloaded from the Duke University websites [24] and, with permission of the creators, stored at a secure website (with help from the QIN Bioinformatics Working Group) for download by the participating QIN sites. Before proceeding to analyze the human breast DCE-MRI data, the participating sites were asked to process the simulated DRO DCE-MRI data using their TM-based algorithms/software tools with the purpose of validating the mathematical formulations implemented in the TM algorithms. The results of DRO data analyses were submitted as parametric maps in Matlab, Nifti, or Nrrd formats.
Human Breast DCE-MRI Data Acquisition and Sharing
As part of the quantitative imaging studies at OHSU as an individual QIN center, breast DCE-MRI data were acquired with consent from patients with locally advanced breast cancer who underwent preoperative neoadjuvant chemotherapy (NACT). Four DCE-MRI sessions were undertaken during the treatment course: pre-NACT (visit 1, V1), after the first cycle of NACT (visit 2, V2), at a NACT midpoint (usually after the third NACT cycle; visit 3), and after the completion of NACT (visit 4). The study was conducted under the approval of the local Institutional Review Board (IRB). For this challenge project, the V1 and V2 data sets from 10 of 16 consecutive patients were shared among the participating QIN sites. The data from the other six patients were not selected because either the V2 data were not acquired or severe motion degraded data quality at V1 and/or V2. All breast MRI studies were performed using a Siemens 3T system with a body coil and a four-channel bilateral phased-array breast coil as the transmitter and receiver, respectively. Following pilot scans and pre-CA T 2 -weighted MRI with fat saturation and T 1 -weighted MRI without fat saturation, axial bilateral DCE-MRI images with fat saturation and full breast coverage were acquired with a three-dimensional (3D) gradient echo-based Time-resolved angiography WIth Stochastic Trajectories (TWIST) sequence, which employs the strategy of k-space undersampling during acquisition and data sharing during reconstruction [26, 27] . DCE-MRI acquisition parameters included 10°flip angle, 2.9/6.2 millisecond echo time/repetition time (TE/TR), a parallel imaging acceleration factor of two, 30 to 34 cm field of view (FOV), 320 × 320 in-plane matrix size, and 1.4-mm slice thickness. The total acquisition time was ∼10 minutes for 32 to 34 image volume sets of 112 to 120 slices each with 18-to 20-second temporal resolution. The CA Gd(HP-DO3A) [ProHance] IV injection (0.1 mmol/kg at 2 ml/s) by a programmable power injector was timed to commence after acquisition of two baseline image volumes, followed by a 20-ml saline flush. Breast tumor regions of interest (ROIs) were drawn by experienced OHSU breast radiologists on post-CA multislice images covering the contrast-enhanced tumor.
For DCE-MRI data sharing, the V1 and V2 raw data sets in Matlab, Nifti, and DICOM formats together with the registered predrawn tumor ROIs from the 10 patients-a total of 20 data sets-were uploaded to the same secure website that housed the DRO data and downloaded by the participating sites. Since the human MRI data were acquired under strictly coded names (e.g., "BreastChemo1" as the last name and "Visit 1" as the first name) and without any entries of identifiable patient health information, no patient health information was ever shared among the QIN sites. The sharing of the anonymous human breast MRI data within the QIN was approved by the OHSU IRB.
Human Breast DCE-MRI Data Analysis
The pharmacokinetic models used by the participating sites for breast tumor DCE-MRI data analysis generally fell into the Translational Oncology Vol. 7, No. 1, 2014 Variation of DCE-MRI in Assessing Therapy Response Huang et al.
following three categories: the TM [23] , the extended TM (ETM) [28, 29] , and the fast exchange regime (FXR)-allowed ShutterSpeed Model (SSM) [17, 30] . Equations 1, 2, and 3 below represent the basic formulations for the TM, ETM, and FXR-SSM, respectively:
where C t (t) represents tissue CA concentration at time t; C p (t′) is the arterial plasma CA concentration time course, or AIF; R 1 *(t) is the tissue apparent longitudinal relaxation rate constant; R 1i is the intracellular longitudinal relaxation rate constant; R 10 is the pre-CA tissue R 1 ; r 1 is the tissue CA relaxivity; and τ i is the mean intracellular water molecule lifetime. Both the TM and ETM neglect the finite intercompartmental water exchange kinetics, assuming the system is in the fast exchange limit condition. As a result, R 1 (t) [or R 1 *(t)] is linearly related to C t (t):
The SSM accounts for the finite water exchange kinetics during the CA passage through the tissue of interest, and consequently, R 1 (t) is not linearly related to C t (t). The FXR version is a two-compartment three-parameter (extracellular and intracellular compartments; K trans , v e , and τ i ) SSM, taking into account transcytolemmal water exchange kinetics but assuming single exponential longitudinal MR signal decay [17, 30] .
Each QIN site had the option of using one or more models for DCE-MRI time-course data fitting. This challenge project focuses on comparisons of different pharmacokinetic models and associated software packages for therapy response assessment. Therefore, to minimize variations in derived kinetic parameters caused by factors other than differences in models and algorithms, such as uncertainties in AIF determination and R 10 quantification, a populationaveraged AIF was provided to each site for analysis of all 20 data sets and the R 10 value was given for each of the 20 studies. The populationaveraged AIF was obtained by averaging individually measured AIFs from an axillary artery in a previous sagittal breast DCE-MRI study [31] [32] [33] , which employed the same CA injection protocol, including dose, injection rate, and injection site (antecubital vein). The average R 10 value for each tumor was determined by comparing signal intensities of pre-CA baseline DCE images with those of the spatially registered proton density images acquired just before DCE-MRI [27] and was used for kinetic modeling of tumor ROI or pixel (within the ROI) DCE data by each site. In addition, the tumor ROI definitions on multiple image slices covering the tumor were also provided for each data set (see above).
The data analysis tools used by the participating sites included software packages built in-house, obtained as free open source, or purchased commercially, as well as prototype research software under development by GE. For results reporting, each site was required to provide mean tumor ROI pharmacokinetic parameter values, the corresponding percentage changes (V2 relative to V1, V21), and parametric maps. Some sites calculated the mean tumor ROI parameters by fitting ROI time-course data from each slice and then averaging the derived slice ROI parameter values, while the others computed Table 1 . Details of Pharmacokinetic Analysis of Human Breast DCE-MRI Data at Participating Sites. 
Determination of Pathologic Response Status
The pathologic response (to NACT) status of each patient with breast cancer was determined by pathologic analyses and comparisons of the pre-NACT core biopsy specimen with the post-NACT resection specimen. The two previously published and validated indices [34, 35] were measured: Relative Change in Tumor Density (RCTD) and Residual Cancer Burden. A pathologic complete response (pCR) is defined as the absence of residual tumor (RCTD = −1.0; Residual Cancer Burden = 0). A pathologic nonresponse (pNR) is defined as tumor cell density in resection specimen equal to or greater than that in core biopsy specimen (RCTD ≥ 0). Pathologic partial response is defined as findings intermediate between pCR and pNR. For this study, the binary classification of pCR and non-pCR (pNR and pathologic partial response) was used for the 10-patient cohort.
Statistical Analysis
For DRO DCE-MRI data analysis, the estimated K trans and v e values from data fitting using site-specific TM algorithms were compared to the simulated "true" K trans and v e values that were used to construct the DRO data.
For human breast DCE-MRI data analysis, descriptive statistical analysis was conducted to summarize the pharmacokinetic parameter values returned by each algorithm/software tool. To assess the reproducibility of each parameter across all algorithms and within each model (i.e., TM, ETM, or SSM), linear mixed models were fit to obtain the maximum likelihood estimates of the intraclass correlation coefficient (ICC) and wCV, and their corresponding 95% confidence intervals (CIs). The concordance correlation coefficients (CCCs) and the corresponding 95% CIs were estimated to represent the level of pairwise linear agreement to a 45°line of which the intercept is forced to be zero. Linear mixed models were fit to determine whether the parameter mean differs for pairwise comparisons of the three kinetic models. Univariate logistic regression (ULR) models were fit to compute the c-statistic, a measure equivalent to the area under the Receiver Operating Characteristic curve, to reflect the predictive ability of each parameter for tumor therapy response. While logarithm transformation will help address the skewed distribution of some parameters, the analysis results are rather robust to using values with or without transformation. Therefore, the original parameter values returned from all algorithms were used for statistical analysis throughout, which was conducted using SAS 9.3 (Cary, NY). SAS macro %ICC9 and %mccc were used for estimations of ICC, wCV, and CCC. represents an estimated K trans value of 0.27 min −1 , 23% smaller than the simulated value of 0.35 min −1 . The estimated v e value in the same square is 11% smaller than the simulated value of 0.01. However, the error is not clearly identifiable in the v e array ( Figure 2B ) due to the small absolute value of the error (0.01 × 11% = 0.0011). The pattern of uniform color in each square of 10 × 10 pixels indicates high reproducibility of the OHSU TM algorithm in analyzing pixel DCE-MRI time-course data constructed with the same K trans and v e combination. Figure 3 shows Human Breast DCE-MRI Analysis
Results
DRO DCE-MRI Data Analysis
Translational Oncology
As summarized in Table 1 , the V1 and V2 DCE-MRI data from the 10 patients were processed by seven institutions using 12 pharmacokinetic analysis algorithms: 6 TM (OHSU, VU, UP, ISM, BWH-GE, and BWH-3D Slicer [36] ), 4 ETM (VU, UM, UW, and BWH-GE), and 2 SSM (OHSU and VU).
Variance analysis. Figure 4A shows the box plots of mean tumor Figure 4B ) show substantial improvement in stability across all the software tools, e.g., the range of the mean values of K trans percentage change obtained from the 12 algorithms is relatively small: −13% to −28%. Figure 5 shows the column graphs of wCV for all five parameters at V1 and V2. wCV cannot be calculated for percentage changes because negative values are not allowed. A smaller wCV value indicates less variation in measurements on the same subject by different approaches. In this study, the wCV values range from 0.25 for τ i at V2 to 0.82 for v p at V1. Among the five DCE-MRI parameters, the v p parameter obtained with the ETM shows the largest variations. 
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Concordance analysis. Concordance correlation analysis was
conducted to assess parameter agreement between any two algorithms within the same pharmacokinetic model (TM, ETM, or SSM). Table 3 tabulates the K trans CCC and 95% CI values for any combination of two algorithms belonging to the same pharmacokinetic model. Though the CCC values can be as low as 0.047 for V2 K trans between two TM software tools, those for K trans percentage change are consistently high -many are greater than 0.9. Similar patterns are also observed for k ep , but not for v e , v p , and τ i . Table 4 lists the ranges of the CCC values for Comparison of model parameter mean values. Table 5 shows the P values for comparisons of the mean DCE-MRI parameters (at V1 and V2, and percentage change) between the three kinetic models using the mixed-models method. Only the means of K trans , v e , and k ep were compared because each model used in this study generates these three parameters. Figure 6 shows the box plots of these three parameters stratified by the models at V1 and V2. Clearly, the K trans and v e values returned by the SSM are substantially greater than those returned by either the TM or ETM, and the differences are statistically significant with very small P values (<.0001 for either TM vs SSM or ETM vs SSM at V1 or V2). It is important to note that despite the significant differences in absolute K trans values at V1 and V2, there are no statistically significant differences in K trans percentage change between the SSM and TM or ETM. For k ep , except for the TM versus SSM comparison of its percentage change, there are no statistically significant differences in its value or percentage change between the models. Early prediction of pCR. The pathologic reviews of the patients' resection and pre-NACT biopsy specimens revealed that in this cohort, three patients achieved pCR following NACT, while the other seven were non-pCRs (all pPRs). The ULR c-statistic values for early discrimination of pCR and non-pCR are listed in Table 6 Figure 8 shows the color tumor K trans maps of a non-pCR ( Figure 8A ) and a pCR ( Figure 8B ) at V1 and V2, computed and generated by all 12 algorithms. For each DCE-MRI data set, the parametric maps are generated for all tumor ROIs on multiple image slices. The K trans maps presented in Figure 8 are from the same image slice (for each subject at each visit) through the center of the tumor. Note that except for the algorithms of BWH-GE_TM and BWH-GE_ETM, all K trans maps are overlaid on post-contrast images. Despite the differences in software algorithms/tools and display color scales, one observation is apparent and common on all the K trans maps: the minimal change in the tumor K trans map from V1 to V2 for the non-pCR is in stark contrast with the dramatic "cooling" of the K trans map color-red to blue (decrease in value)-from V1 to V2 for the pCR. The color k ep maps (not shown here) show nearly identical patterns for the same two patients.
Discussion
Though DCE-MRI is becoming one of the imaging modalities of choice for assessment of cancer therapy response in early phase clinical trials, systematic comparison and validation of methods for pharmacokinetic analysis of DCE-MRI time-course data are needed to determine sources of parameter errors and variations, examine the effects of these variations on evaluation of tumor therapy response, and reach consensus on the best practice for DCE-MRI in a multicenter clinical trial. To the best of our knowledge, this is the first study in which shared DCE-MRI data from a longitudinal therapy monitoring study are analyzed by multiple centers using site-specific pharmacokinetic models and associated algorithms. The overall purpose of this multicenter DCE-MRI data analysis challenge is to evaluate variations in DCE-MRI prediction of breast cancer therapy response that are caused by differences in pharmacokinetic models and associated software algorithms only.
With the exception of the 2 SSM algorithms, the other 10 algorithms employed in this challenge are the commonly used TM and ETM. The reasonable results from fittings of the TM-simulated DRO data with five of the six involved TM algorithms confirm the accuracy of mathematical formulation and software coding in these TM software packages. The large errors (>20%) in estimated K trans were mostly resulted from fittings of DRO data with high K trans and low v e combinations, which were generally not the cases for the studied breast tumors. Though the reasons for large errors from these particular K trans and v e combinations warrant further investigations, a complete and in-depth analysis of the DRO data-fitting results is beyond the scope of this manuscript. Despite the fixed inputs of tumor ROI definition, AIF, and T 10 in analyzing the shared human data for all algorithms, there are substantial variations in returned Figure 4A ). It is not surprising that K trans and v e parameters derived from SSM analysis are significantly greater than their TM or ETM counterparts at either V1 or V2 ( Figure 6 and Table 5 ), as the same patterns have been observed in DCE-MRI studies of tumors in different organs [17, 27, [31] [32] [33] [37] [38] [39] . The differences between the SSM and TM in derived K trans and v e parameter values are systematic ones directly resulted from inclusion or exclusion of the water exchange effects by the SSM and TM, respectively. The exact reason for the out-of-range small K trans and v e values returned by the BWH-3D Slicer TM algorithm is unclear. DRO data fitting by the same algorithm consistently returned K trans and v e values with >10% errors for all combinations of simulated K trans and v e values with maximum error of 71% for K trans estimation. Heye et al. observed up to 10-fold to 100-fold difference in K trans and v e values obtained with different commercial software packages [22] . They attributed these massive discrepancies to possible differences in scaling factors used by commercial vendors for reporting or displaying estimated pharmacokinetic parameters. The same reason may be the cause of the two-fold to four-fold parameter value difference observed in this study between the BWH-3D Slicer TM software tool and most other algorithms. Most of the DCE-MRI parametric maps generated from the shared human data were spatially heterogeneous ( Figure 8) It is reasonable that the agreement in the three common DCE-MRI parameters (K trans , v e , and k ep ) that are obtainable by all three kinetic models is generally improved when only algorithms within the same kinetic model are compared, as opposed to comparisons across all 12 algorithms (Table 2) . However, there are still substantial variations in returned parameter values by different software tools based on the same model. Besides the scaling factor variation that may have contributed to the markedly small K trans and v e values obtained with the BWH-3D Slicer TM algorithm, other contributions to parameter variations among algorithms based on the same model may come from differences in fixed physiological and MR parameters (such as hematocrit, pre-contrast blood T 1 , and so on), contrast arrival time (or AIF shift), AIF curve resampling strategy, and goodness of fitting criteria employed in each algorithm. These factors were not controlled for any algorithm used in this data analysis challenge. It should be noted that the BWH-3D Slicer tool is the only one of the tested software packages that is available as free open source software. Availability of the software source code can facilitate reproducibility of results [40] and aid further investigation of sources of variability and inconsistency in comparison with other algorithm implementations.
One important observation that is not available in the study by Heye et al. [22] but is afforded by the longitudinal nature of the shared DCE-MRI data in this study is the agreement in parameter percentage change (V2 relative to V1) among the algorithms. It is interesting and important to note that agreements in parameter percentage changes are generally better than those of the absolute parameter values at either V1 or V2 regardless whether the comparisons are made across all algorithms or within each kinetic model (Figure 4  and Tables 2, 3 , and 4). The CCC values of K trans at V1 and V2 are quite small for any pairwise comparison of TM algorithms that includes the BWH-3D Slicer TM algorithm, but those of the corresponding K trans percentage changes are drastically increased (Table 3) , indicating greater agreement between the pair of algorithms. The reason for such improvement in agreement among the algorithms is probably partial cancellation of systematic differences (or variations) among different algorithms in percentage change calculations. For example, if the application of a scaling factor in the BWH-3D Slicer TM algorithm caused unusually small K trans and v e values, the effects of the scaling factor were canceled in calculating percentage changes of these parameters, resulting in percentage change values comparable to those obtained with the other algorithms.
Among the 12 algorithms used in this challenge, only the 4 based on the ETM generate the v p parameter through data fitting. Compared to the K trans and v e parameters estimated with these four ETM algorithms, the variance in v p is relatively high, reflected by its large wCV ( Figure 5 ), small ICC (see above), and small CCC (Table 4) values. This is most likely due to the relatively low temporal resolution Figure 8 . V1 and V2 single slice tumor K trans parametric maps generated by all 12 algorithms for a non-pCR (A) and a pCR (B). The primary tumor was in the left breast of the non-pCR and the right breast of the pCR. The color K trans maps are overlaid on post-contrast or pre-contrast DCE images. Although the color scales for these maps are different between subjects and among algorithms, they are kept the same for V1 and V2 maps generated by the same algorithm for the same subject.
(∼20 seconds) of the raw breast DCE-MRI data. v p is a parameter of the vascular compartment that contributes a significant fraction of the DCE-MRI signal only during the early phase of rapid signal rise. The inability of the data acquisition protocol used in this study to accurately capture the DCE curve shape during this time window leads to low accuracy and precision in v p quantification [20, 21] and hence its high variance. A simulation study [41] shows that at least 4-second temporal resolution is needed for accurate v p estimation from breast DCE-MRI data. Given clinical preference for full breast coverage and high spatial resolution in breast MRI, such high temporal resolution is difficult to achieve even with combined use of k-space undersampling scheme and parallel imaging acceleration, as is the case for the shared breast data in this study. The low accuracy and precision of the v p parameter, and possibly the resultant reduced capability in prediction of therapy response found (see below) in this study, demonstrate the importance of proper model selection for pharmacokinetic analysis of DCE-MRI data. Using a model that includes the vascular compartment to fit low temporal resolution DCE-MRI data will introduce more errors and uncertainties in the derived parameters [20, 21] and thus diminish the effectiveness of DCE-MRI for evaluation of therapy response.
Despite the considerable variances in parameter values obtained with different algorithms, it is rather encouraging within the context of therapy response assessment, however, that nearly all 12 algorithms provided good to excellent (ULR c ≥ 0.8) early prediction of pathologic response using V2 K trans and k ep or their corresponding percentage changes (V2 relative to V1) as predictive markers (Table 6 ). For V2 K trans and k ep , there are 9 and 8 (of 12) algorithms providing excellent predictions with ULR c ≥ 0.9, respectively, while for K trans and k ep percentage changes, the numbers of algorithms with ULR c ≥ 0.9 are 9 and 10 (of 12), respectively. The predictive abilities of the V2 K trans and k ep parameters across all algorithms may be due to 1) the substantial decreases in perfusion and permeability of the three pCR tumors in comparison with the seven non-pCR tumors outweighed parameter variations introduced by algorithm differences, and/or 2) the interalgorithm variations are systematic, i.e., error signs in parameter misestimations are the same for both pCR and non-pCR tumors: overestimation or underestimation for both groups. The second, potentially the most important, reason is clearly illustrated in Figure 7B for V2 K trans , where the black (pCR) and red (non-pCR) data points more or less move in the same up or down direction going from one algorithm to another, maintaining similar pCR versus nonpCR data point gaps among the algorithms and thus similar discriminative capabilities. The predictive capabilities of K trans and k ep percentage changes across all algorithms are most likely due to cancellation of the interalgorithm systematic errors (or variations) in percentage change calculation. Figure 7C shows relatively stable distribution of K trans percentage changes for both pCRs and nonpCRs across the 12 algorithms in contrast to absolute V1 ( Figure 7A ) and V2 ( Figure 7B) K trans values that are more variable across algorithms. Similar patterns can also be seen in Figure 4 . With less systematic errors (variations), the more stable K trans and k ep percentage change values allowed the tested algorithms to estimate the intrinsic differences between the pCRs and non-pCRs and gave fairly uniform predictions of therapy response.
In this multicenter data analysis challenge, the three major aspects in DCE-MRI data acquisition and analysis that can cause significant parameter variations (i.e., tumor ROI definition, T 10 measurement, and AIF determination) were controlled to focus on comparisons of pharmacokinetic models and associated algorithms in assessment of breast cancer response to NACT. The results suggest that variations in DCE-MRI parameters caused by differences in models/algorithms only are mostly systematic. As a result, all models/algorithms performed fairly consistently in prediction of therapy response, especially using the percentage change metrics in which the interalgorithm systematic variations are significantly reduced. In this particular study setting, K trans and k ep percentage changes computed with most of the algorithms provided excellent early prediction of breast cancer response to NACT. The introduction of variations in tumor ROI definition and errors in T 10 and AIF determinations in a multicenter clinical trial setting where DCE-MRI data are acquired and analyzed at each individual site will add random errors and variations in derived DCE-MRI parameters. This will not only cause more severe parameter variance but also affect DCE-MRI performance in evaluation of therapy response. Therefore, it is of paramount importance in a multicenter clinical trial to strictly standardize data acquisition protocol (such as temporal resolution) and perform frequent scanner quality assurance/quality control (QA/QC) [9] [10] [11] to minimize interscanner platform or interacquisition protocol random errors in quantification of T 10 and AIF in a longitudinal DCE-MRI study of tumor therapy response. Random errors due to variations in manual drawing of tumor ROI are difficult to avoid. Use of automatic or semiautomatic algorithms for tumor ROI definition may help mitigate such errors. One possible approach to reduce random errors and variations in a multicenter trial and improve performance consistency in response assessment is centralized DCE-MRI data analysis in which fixed inputs for pharmacokinetic modeling, such as single observer-defined tumor ROIs and population-averaged AIF, could be used.
In conclusion, considerable parameter variations were observed when shared breast DCE-MRI data sets were analyzed with different algorithms based on the TM, ETM, and SSM in a multicenter data analysis challenge. However, nearly all algorithms provided good to excellent early prediction of breast cancer response to therapy using the K trans and k ep parameters after the first cycle of NACT and their percentage changes, suggesting that the utility of DCE-MRI for assessment of therapy response is not diminished by interalgorithm systematic variations.
